173 related articles for article (PubMed ID: 17107284)
21. Nelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma.
Kadia TM; Gandhi V
Expert Rev Hematol; 2017 Jan; 10(1):1-8. PubMed ID: 27869523
[TBL] [Abstract][Full Text] [Related]
22. Potent orally bioavailable purine nucleoside phosphorylase inhibitor BCX-4208 induces apoptosis in B- and T-lymphocytes--a novel treatment approach for autoimmune diseases, organ transplantation and hematologic malignancies.
Bantia S; Parker C; Upshaw R; Cunningham A; Kotian P; Kilpatrick JM; Morris P; Chand P; Babu YS
Int Immunopharmacol; 2010 Jul; 10(7):784-90. PubMed ID: 20399911
[TBL] [Abstract][Full Text] [Related]
23. A purine nucleoside phosphorylase (PNP) inhibitor induces apoptosis via caspase-3-like protease activity in MOLT-4 T cells.
Posmantur R; Wang KK; Nath R; Gilbertsen RB
Immunopharmacology; 1997 Oct; 37(2-3):231-44. PubMed ID: 9403342
[TBL] [Abstract][Full Text] [Related]
24. Determinants of sensitivity of human T-cell leukemia CCRF-CEM cells to immucillin-H.
Huang M; Wang Y; Gu J; Yang J; Noel K; Mitchell BS; Schramm VL; Graves LM
Leuk Res; 2008 Aug; 32(8):1268-78. PubMed ID: 18279955
[TBL] [Abstract][Full Text] [Related]
25. Mechanisms of 2'-deoxyguanosine toxicity in mouse T-lymphoma cells with purine nucleoside phosphorylase deficiency and resistance to inhibition of ribonucleotide reductase by dGTP.
Duan DS; Nagashima T; Hoshino T; Waldman F; Pawlak K; Sadee W
Biochem J; 1990 Jun; 268(3):725-31. PubMed ID: 2114100
[TBL] [Abstract][Full Text] [Related]
26. One-third-the-sites transition-state inhibitors for purine nucleoside phosphorylase.
Miles RW; Tyler PC; Furneaux RH; Bagdassarian CK; Schramm VL
Biochemistry; 1998 Jun; 37(24):8615-21. PubMed ID: 9628722
[TBL] [Abstract][Full Text] [Related]
27. Nelarabine (Arranon) for T-cell acute lymphoblastic leukemia.
Med Lett Drugs Ther; 2006 Feb; 48(1228):14-5. PubMed ID: 16467734
[No Abstract] [Full Text] [Related]
28. Effect of 9-benzyl-9-deazaguanine, a potent inhibitor of purine nucleoside phosphorylase, on the cytotoxicity and metabolism of 6-thio-2'-deoxyguanosine.
Parker WB; Allan PW; Niwas S; Montgomery JA; Bennett LL
Cancer Res; 1994 Apr; 54(7):1742-5. PubMed ID: 8137289
[TBL] [Abstract][Full Text] [Related]
29. Structure of human PNP complexed with ligands.
Canduri F; Silva RG; dos Santos DM; Palma MS; Basso LA; Santos DS; de Azevedo WF
Acta Crystallogr D Biol Crystallogr; 2005 Jul; 61(Pt 7):856-62. PubMed ID: 15983407
[TBL] [Abstract][Full Text] [Related]
30. Mechanisms of deoxyguanosine lymphotoxicity. Human thymocytes, but not peripheral blood lymphocytes accumulate deoxy-GTP in conditions simulating purine nucleoside phosphorylase deficiency.
Fairbanks LD; Taddeo A; Duley JA; Simmonds HA
J Immunol; 1990 Jan; 144(2):485-91. PubMed ID: 2104895
[TBL] [Abstract][Full Text] [Related]
31. In vitro efficacy of forodesine and nelarabine (ara-G) in pediatric leukemia.
Homminga I; Zwaan CM; Manz CY; Parker C; Bantia S; Smits WK; Higginbotham F; Pieters R; Meijerink JP
Blood; 2011 Aug; 118(8):2184-90. PubMed ID: 21730354
[TBL] [Abstract][Full Text] [Related]
32. Correction of purine nucleoside phosphorylase deficiency by retroviral-mediated gene transfer in mouse S49 T cell lymphoma: a model for gene therapy of T cell immunodeficiency.
Foresman MD; Nelson DM; McIvor RS
Hum Gene Ther; 1992 Dec; 3(6):625-31. PubMed ID: 1482702
[TBL] [Abstract][Full Text] [Related]
33. Structural basis for inhibition of human PNP by immucillin-H.
Filgueira de Azevedo W; Canduri F; Marangoni dos Santos D; Pereira JH; Dias MV; Silva RG; Mendes MA; Basso LA; Palma MS; Santos DS
Biochem Biophys Res Commun; 2003 Oct; 309(4):917-22. PubMed ID: 13679061
[TBL] [Abstract][Full Text] [Related]
34. Different pathways for deoxyguanosine toxicity in T-lymphocytes of various developmental stages.
Scharenberg JG; Rijkers GT; Spaapen LJ; Toebes EA; Rijksen G; Duran M; Staal GE; Zegers BJ
Int J Immunopharmacol; 1988; 10(6):675-86. PubMed ID: 2974022
[TBL] [Abstract][Full Text] [Related]
35. Diagnosis of immunodeficiency caused by a purine nucleoside phosphorylase defect by using tandem mass spectrometry on dried blood spots.
la Marca G; Canessa C; Giocaliere E; Romano F; Malvagia S; Funghini S; Moriondo M; Valleriani C; Lippi F; Ombrone D; Della Bona ML; Speckmann C; Borte S; Brodszki N; Gennery AR; Weinacht K; Celmeli F; Pagel J; de Martino M; Guerrini R; Wittkowski H; Santisteban I; Bali P; Ikinciogullari A; Hershfield M; Notarangelo LD; Resti M; Azzari C
J Allergy Clin Immunol; 2014 Jul; 134(1):155-9. PubMed ID: 24767876
[TBL] [Abstract][Full Text] [Related]
36. Novel agents in development for peripheral T-cell lymphoma.
O'Connor OA
Semin Hematol; 2010 Apr; 47 Suppl 1():S11-4. PubMed ID: 20359580
[TBL] [Abstract][Full Text] [Related]
37. Synthesis of analogs of forodesine HCl, a human purine nucleoside phosphorylase inhibitor-Part II.
Kamath VP; Xue J; Juarez-Brambila JJ
Bioorg Med Chem Lett; 2009 May; 19(10):2627-9. PubMed ID: 19386496
[TBL] [Abstract][Full Text] [Related]
38. [Tight binding transition state analogues of purine nucleoside phosphorylase--meaning, design and properties].
Lewandowicz A
Postepy Biochem; 2004; 50(3):218-27. PubMed ID: 15822751
[No Abstract] [Full Text] [Related]
39. Synthesis of analogs of forodesine HCl, a human purine nucleoside phosphorylase inhibitor-Part I.
Kamath VP; Xue J; Juarez-Brambila JJ; Morris CB; Ganorkar R; Morris PE
Bioorg Med Chem Lett; 2009 May; 19(10):2624-6. PubMed ID: 19386498
[TBL] [Abstract][Full Text] [Related]
40. Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia.
Balakrishnan K; Verma D; O'Brien S; Kilpatrick JM; Chen Y; Tyler BF; Bickel S; Bantia S; Keating MJ; Kantarjian H; Gandhi V; Ravandi F
Blood; 2010 Aug; 116(6):886-92. PubMed ID: 20427701
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
